| URL | https://firstwordpharma.com/story/6062467 |
| Source | FirstWord Pharma |
| Date Published | 09/15/2025 |
| Company/Division name | Emergent BioSolutions |
| Parent company | Emergent Biosolutions |
| Type of work | Manufacturing |
| Reshoring category: | Reshoring |
| Year reshoring announced: | 2025 |
| Domestically, the work will be done: | In-house |
| Capital investment ($): | 17 |
| If relevant, work nearshored to: | - |
| Industry(ies): | Chemicals |
| Product(s) reshored | EMBEXA® (brincidofovir), a Smallpox Antiviral |
| What domestic positive factors made reshoring more attractive? | Government Incentives, Impact on domestic economy |